

**Reference List 2007-2017**

No. 265 - 535

**2007**

- (265) Axelsson CK, Mouridsen HT, Düring M, Møller S. Axillary staging during surgery for breast cancer. *Br J Surg* 2007 Mar;94(3):304-9.
- (266) Dalton SO, Ross L, Düring M, Carlsen K, Mortensen PB, Lynch J, Johansen C. Influence of socioeconomic factors on survival after breast cancer--a nationwide cohort study of women diagnosed with breast cancer in Denmark 1983-1999. *Int J Cancer*. 2007 Dec 1;121(11):2524-31.
- (267) Ejlertsen B, Hojris I, Hansen S, Moholt K, Kristensen B, Mouridsen HT et al. WITHDRAWN: Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group. *Breast* 2007 May 29.
- (268) Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Cold S, Edlund P et al. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. *Eur J Cancer* 2007 March;43(5):877-84.
- (269) Grabau D, Jensen MB, Rank F, Blichert-Toft M. Axillary lymph node micrometastases in invasive breast cancer: national figures on incidence and overall survival. *APMIS* 2007 July;115(7):828-37.
- (270) Groenvold M, Fayers PM, Petersen MA, Sprangers MA, Aaronson NK, Mouridsen HT. Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff. *Breast Cancer Res Treat* 2007 June;103(2):185-95.
- (271) Groenvold M, Petersen MA, Idler E, Bjørner JB, Fayers PM, Mouridsen HT. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. *Breast Cancer Res Treat* 2007 October;105(2):209-19.
- (272) Gronvold M, Jensen AB. [Patients' experience of breast cancer treatment]. *Ugeskr Laeger* 2007 September 10;169(37):3114-7.
- (273) Husted MA, Haugaard K, Soerensen J, Bokmand S, Friis E, Holtveg H et al. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: A study from the Danish Breast Cancer Cooperative Group. *Breast* 2007 October 8.
- (274) Johansen J, Overgaard J, Overgaard M. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation. *Acta Oncol* 2007;46(4):525-33.
- (275) Offersen BV, Riisbro R, Knoop A, Brunner N, Overgaard J. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer. *Acta Oncol* 2007;46(6):782-91.
- (276) Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. *Radiother Oncol* 2007 March;82(3):247-53.

(277) Peuckmann V, Ekholm O, Rasmussen NK, Moller S, Groenvold M, Christiansen P et al. Health-related quality of life in long-term breast cancer survivors: nationwide survey in Denmark. *Breast Cancer Res Treat* 2007 July;104(1):39-46.

(278) Talman ML, Jensen MB, Rank F. Invasive lobular breast cancer. Prognostic significance of histological malignancy grading. *Acta Oncol* 2007;46(6):803-9.

## 2008

(279) Ahern TP, Larsson H, Garne JP, Cronin-Fenton DP, Sorensen HT, Lash TL. Trends in breast-conserving surgery in Denmark, 1982-2002. *Eur J Epidemiol* 2008;23(2):109-14.

(280) Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Borresen-Dale AL et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. *Acta Oncol* 2008;47(4):600-7.

(281) Andersen J, Kamby C, Ejlertsen B, Cold S, Ewertz M, Jacobsen EH et al. Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). *Acta Oncol* 2008;47(4):718-24.

(282) Andersen SB, Vejborg I, von Euler-Chelpin M. Participation behaviour following a false positive test in the Copenhagen mammography screening programme. *Acta Oncol* 2008;47(4):550-5.

(283) Andersson M, Jensen MB, Engholm G, Henrik SH. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. *Acta Oncol* 2008;47(4):755-64.

(284) Axelsson CK, Jonsson PE. Sentinel lymph node biopsy in operations for recurrent breast cancer. *Eur J Surg Oncol* 2008 Jun;34(6):626-30.

(285) Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P. Adverse bone effects during pharmacological breast cancer therapy. *Acta Oncol* 2008;47(4):747-54.

(286) Blichert-Toft M, Nielsen M, Duing M, Moller S, Rank F, Overgaard M et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. *Acta Oncol* 2008;47(4):672-81.

(287) Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group--DBCG: History, organization, and status of scientific achievements at 30-year anniversary. *Acta Oncol* 2008;47(4):497-505.

(288) Christensen S, Zachariae R, Jensen AB, Vaeth M, Moller S, Ravnsbaek J et al. Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer. *Breast Cancer Res Treat* 2008 February 16.

(289) Christiansen P, Al-Suliman N, Bjerre K, Moller S. Recurrence pattern and prognosis in low-risk breast cancer patients--data from the DBCG 89-A programme. *Acta Oncol* 2008;47(4):691-703.

(290) Christiansen P, Friis E, Balslev E, Jensen D, Moller S. Sentinel node biopsy in breast cancer: five years experience from Denmark. *Acta Oncol* 2008;47(4):561-8.

- (291) Ejlersen B, Mouridsen HT, Jensen MB. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premenopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. *Acta Oncol* 2008;47(4):662-71.
- (292) Ejlersen B, Jensen MB, Mouridsen HT, Andersen J, Cold S, Jakobsen E et al. DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients. *Acta Oncol* 2008;47(4):709-17.
- (293) Ewertz M, Kempel MM, Durring M, Jensen MB, Andersson M, Christiansen P et al. Breast conserving treatment in Denmark, 1989-1998. A nationwide population-based study of the Danish Breast Cancer Co-operative Group. *Acta Oncol* 2008;47(4):682-90.
- (294) Friis E, Galatius H, Garne JP. Organized nation-wide implementation of sentinel lymph node biopsy in Denmark. *Acta Oncol* 2008;47(4):556-60.
- (295) Henriksen KL, Sonne-Hansen K, Kirkegaard T, Frogne T, Lykkesfeldt AE. Development of new predictive markers for endocrine therapy and resistance in breast cancer. *Acta Oncol* 2008;47(4):795-801.
- (296) Hernandez RK, Sorensen HT, Jacobsen J, Pedersen L, Lash TL. Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: a null association. *Cancer Epidemiol Biomarkers Prev* 2008 Sep;17(9):2509-11.
- (297) Holmich LR, Durring M, Henriksen TF, Krag C, Tange UB, Kjoller K, et al. Delayed breast reconstruction with implants after invasive breast cancer does not impair prognosis. *Ann Plast Surg* 2008 Jul;61(1):11-8.
- (298) Husted MA, Haugaard K, Soerensen J, Bokmand S, Friis E, Holtveg H, et al. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group. *Breast* 2008 Apr;17(2):138-47.
- (299) Jensen AR, Madsen AH, Overgaard J. Trends in breast cancer during three decades in Denmark: stage at diagnosis, surgical management and survival. *Acta Oncol* 2008;47(4):537-44.
- (300) Joergensen LE, Gunnarsdottir KA, Langg C, Moeller S, Rasmussen BB. Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996-2001. *Breast* 2008 August 8.
- (301) Johansen H, Kaae S, Jensen MB, Mouridsen HT. Extended radical mastectomy versus simple mastectomy followed by radiotherapy in primary breast cancer. A fifty-year follow-up to the Copenhagen Breast Cancer randomised study. *Acta Oncol* 2008;47(4):633-8.
- (302) Kiaer HW, Laenkholm AV, Nielsen BB, Bjerre KD. Classical pathological variables recorded in the Danish Breast Cancer Cooperative Group's register 1978-2006. *Acta Oncol* 2008;47(4):778-83.
- (303) Kristensen B, Ejlersen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. *Acta Oncol* 2008;47(4):740-6.
- (304) Kroman N. Timing of breast cancer surgery in relation to the menstrual cycle--the rise and fall of a hypothesis. *Acta Oncol* 2008;47(4):576-9.

- (305) Kroman N, Jensen MB, Wohlfahrt J, Ejlersen B. Pregnancy after treatment of breast cancer--a population-based study on behalf of Danish Breast Cancer Cooperative Group. *Acta Oncol* 2008;47(4):545-9.
- (306) Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J et al. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. *Acta Oncol* 2008;47(4):591-9.
- (307) Kyndi M, Sorensen FB, Knudsen H, Alsner J, Overgaard M, Nielsen HM et al. Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c. *Acta Oncol* 2008;47(4):608-17.
- (308) Kyndi M, Overgaard M, Nielsen HM, Sorensen FB, Knudsen H, Overgaard J. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: A subgroup analysis of DBCG 82 b&c. *Radiother Oncol* 2008 May 7.
- (309) Kyndi M. Biological markers and response to adjuvant radiotherapy i high-risk breast cancer Faculty of health sciences, University of Aarhus; 2008.
- (310) Kyndi M, Sorensen FB, Knudsen H, Jan A, Overgaard M, Nielsen HM et al. Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials. *Breast Cancer Res* 2008 March 20;10(2):R24.
- (311) Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. *J Clin Oncol* 2008 March 20;26(9):1419-26.
- (312) Laenkholm AV, Jensen MB, Kroman N, Rank F. Breast cancer in situ. From pre-malignant lesion of uncertain significance to well-defined non-invasive malignant lesion. The Danish Breast Cancer Cooperative Group Register 1977-2007 revisited. *Acta Oncol* 2008;47(4):765-71.
- (313) Langkjer ST, Ejlersen B, Mouridsen H, Andersen J, Nielsen MM, Moller KA et al. Vinorelbine as first-line or second-line therapy for advanced breast cancer: a Phase I-II trial by the Danish Breast Cancer Co-operative Group. *Acta Oncol* 2008;47(4):735-9.
- (314) Lauridsen MC, Overgaard M, Overgaard J, Hessov IB, Christiansen P. Shoulder disability and late symptoms following surgery for early breast cancer. *Acta Oncol* 2008;47(4):569-75.
- (315) Madsen AH, Jensen AR, Christiansen P, Garne JP, Cold S, Ewertz M et al. Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group. *Acta Oncol* 2008;47(2):239-47.
- (316) Madsen AH, Haugaard K, Soerensen J, Bokmand S, Friis E, Holtveg H et al. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: A study from the Danish Breast Cancer Cooperative Group. *Breast* 2008 April;17(2):138-47.
- (317) Mouridsen HT, Bjerre KD, Christiansen P, Jensen MB, Moller S. Improvement of prognosis in breast cancer in Denmark 1977-2006, based on the nationwide reporting to the DBCG Registry. *Acta Oncol* 2008;47(4):525-36.
- (318) Møller S, Jensen MB, Ejlersen B, Bjerre KD, Larsen M, Hansen HB et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. *Acta Oncol* 2008;47(4):506-24.

- (319) Nielsen KV, Ejlersten B, Moller S, Jorgensen JT, Knoop A, Knudsen H et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. *Acta Oncol* 2008;47(4):725-34.
- (320) Offersen BV, Alsner J, Ege OK, Riisbro R, Brunner N, Sorensen FB et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. *Acta Oncol* 2008;47(4):618-32.
- (321) Overgaard J. DBCG: the Danish Breast Cancer Cooperative Group--a 30-year struggle for better breast cancer treatment in Denmark. *Acta Oncol* 2008;47(4):491-6.
- (322) Overgaard M, Christensen JJ. Postoperative radiotherapy in DBCG during 30 years. Techniques, indications and clinical radiobiological experience. *Acta Oncol* 2008;47(4):639-53.
- (323) Rasmussen BB, Andersson M, Christensen IJ, Moller S. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables. *Acta Oncol* 2008;47(4):784-8.
- (324) Roslind A, Knoop AS, Jensen MB, Johansen JS, Nielsen DL, Price PA, Balslev E. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. *Breast Cancer Res Treat* 2008 Nov;112(2):275-85
- (325) Stralman K, Mollerup CL, Kristoffersen US, Elberg JJ. Long-term outcome after mastectomy with immediate breast reconstruction. *Acta Oncol* 2008;47(4):704-8.
- (326) Talman ML, Rasmussen BB, Andersen J, Christensen IJ. Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. *Acta Oncol* 2008;47(4):789-94.
- (327) Thomassen M, Hansen TV, Borg A, Lianee HT, Wikman F, Pedersen IS et al. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. *Acta Oncol* 2008;47(4):772-7.
- (328) Thomsen MS, Berg M, Nielsen HM, Pedersen AN, Overgaard M, Ewertz M et al. Post-mastectomy radiotherapy in Denmark: from 2D to 3D treatment planning guidelines of The Danish Breast Cancer Cooperative Group. *Acta Oncol* 2008;47(4):654-61.
- (329) Würtz SØ, Møller S, Mouridsen H, Hertel PB, Friis E, Brünner N. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. *Mol Cell Proteomics*. 2008 Feb; 7(2): 424-30.
- (330) Wurtz SO, Schrohl AS, Mouridsen H, Brunner N. TIMP-1 as a tumor marker in breast cancer--an update. *Acta Oncol* 2008;47(4):580-90.

## 2009

- (331) Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. *Cancer Epidemiol Biomarkers Prev* 2009 Sep;18(9):2562-4.
- (332) Axelsson CK, Daring M, Christiansen PM, Wamberg PA, Soe KL, Moller S. Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer. *Br J Surg* 2009 Jan;96(1):40-6.

- (333) Christensen S, Zachariae R, Jensen AB, Vaeth M, Moller S, Ravnsbaek J, et al. Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer. *Breast Cancer Res Treat* 2009 Jan;113(2):339-55.
- (334) Ejlersen B, Jensen MB, Rank F, Rasmussen BB, Christiansen P, Kroman N, et al. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. *J Natl Cancer Inst* 2009 May 20;101(10):729-35.
- (335) Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. *JAMA*. 2009 Nov 11;302(18):1985-92.
- (336) Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlersen B, Mouridsen HT. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. *Acta Oncol*. 2009; 48(4):522-31.
- (337) Hernandez RK, Sorensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. *Cancer* 2009 Oct 1;115(19):4442-9.
- (338) Kyndi M, Overgaard M, Nielsen HM, Sorensen FB, Knudsen H, Overgaard J. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. *Radiother Oncol* 2009 Jan;90(1):74-9.
- (339) Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlersen B, Mouridsen HT. In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer. *BMC Cancer*. 2009 Jun 16; 9: 185.
- (340) Olsen AH, Bihrmann K, Jensen MB, Vejborg I, Lyng E. Breast density and outcome of mammography screening: a cohort study. *Br J Cancer* 2009 Apr 7;100(7):1205-8.
- (341) Peuckmann V, Ekholm O, Rasmussen NK, Groenvold M, Christiansen P, Moller S, et al. Chronic pain and other sequelae in long-term breast cancer survivors: nationwide survey in Denmark. *Eur J Pain* 2009 May;13(5):478-85.
- (342) Peuckmann V, Ekholm O, Sjogren P, Rasmussen NK, Christiansen P, Moller S, et al. Health care utilisation and characteristics of long-term breast cancer survivors: nationwide survey in Denmark. *Eur J Cancer* 2009 Mar;45(4):625-33.
- (343) Willemoie GL, Hertel PB, Bartels A, Jensen MB, Balslev E, Rasmussen BB, et al. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. *Eur J Cancer* 2009 Sep;45(14):2528-36.

## 2010

- (344) Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L, Fourquet A, Gee J, Holli K, Jakesz R, Kerin M, Mansel R, Nicholson R, Pienkowski T, Pinder S, Sundquist M, van de Vijver M, Ellis I. ONCOPOOL - a European database for 16,944 cases of breast cancer. *Eur J Cancer* 2010 Jan;46(1):56-71.

- (345) Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Rasmussen BB, Willemoe GL, Hertel PB, Knoop AS, Mouridsen HT, Brüner N. HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients. *J Clin Oncol* 2010 Feb 20;28(6):984-90.
- (346) Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Andersson M, Kamby C, Knoop AS; Danish Breast Cancer Cooperative Group. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. *Cancer*. 2010 May 1;116(9):2081-9.
- (347) Gunnarsdóttir KA, Jensen MB, Zahrieh D, Gelber RD, Knoop A, Bonetti M, Mouridsen H, Ejlertsen B. CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. *Breast Cancer Res Treat*. 2010 Aug;123(1):163-9.
- (348) Gärtner R, Jensen MB, Kronborg L, Ewertz M, Kehlet H, Kroman N. Self-reported arm-lymphedema and functional impairment after breast cancer treatment--a nationwide study of prevalence and associated factors. *Breast*. 2010 Dec;19(6):506-15.
- (349) Mouridsen HT, Lønning P, Beckmann MW, Blackwell K, Doughty J, Gligorov J, Llombart-Cussac A, Robidoux A, Thürlimann B, Gnant M. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. *Anticancer Ther*. 2010; 10 (11): 1825-1836.
- (350) Nielsen KV, Müller S, Møller S, Schönau A, Balslev E, Knoop AS, Ejlertsen B. Aberrations of ERBB2 and TOP2A genes in breast cancer. *Mol Oncol*. 2010 Apr; 4(2): 161-8.

## 2011

- (351) Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, Karlsson P, Tange UB, Sørensen PG, Møller S, Bergh J, Langkjær ST. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. *J Clin Oncol*. 2011 Jan 20; 29(3): 264-71.
- (352) Azim HA Jr, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, Peccatori FA. Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies. *Eur J Cancer* 2011 Jan; 47(1):74-83.
- (353) Christiansen P, Bjerre K, Ejlertsen B, Jensen M-B, Rasmussen BB, Lænkholm A-V, Kroman N, Ewertz M, Offersen B, Toftdahl DB, Møller S, Mouridsen HT; on behalf of the Danish Breast Cancer Cooperative Group. Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark. *J Natl Cancer Inst*. 2011 Sep 21; 103(18):1363-72.
- (354) Damkjær LH, Deltour I, Suppli NP, Christensen J, Kroman NT, Johansen C & Dalton SO. Breast cancer and early retirement: Associations with disease characteristics, treatment, comorbidity, social position and participation in a six-day rehabilitation course in a register-based study in Denmark. *Acta Oncol* 2011; 50: 274-281.
- (355) Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y and Peto R; The writing committee on behalf of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of

- individual patient data for 10 801 women in 17 randomised trials. *Lancet* 2011 Nov 12; 378(9804):1707-16.
- (356) Di Leo A, Desmedt C, Bartlett JMS, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves Prof C J, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M, for the HER2/TOP2A Meta-analysis Study Group. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. *Lancet Oncol.* 2011 Nov; 12(12):1134-42.
- (357) Eckhoff L, Nielsen M, Moeller S, Knoop A. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. *Acta Oncol.* 2011 Oct; 50(7): 1075-82.
- (358) Edlund P, Ahlgren J, Bjerre K, Andersson M, Bergh J, Mouridsen H, Holmberg SB, Bengtsson NO, Jakobsen E, Møller S, Lindman H, Blomqvist C. Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. *Acta Oncol.* 2011 Apr; 50(3): 329-37.
- (359) Ewertz M, Jensen MB, Gunnarsdóttir KA, Højris I, Jakobsen EH, Nielsen D, Stenbygaard LE, Tange UB, Cold S. Effect of Obesity on Prognosis After Early-Stage Breast Cancer. *J Clin Oncol* 2011 Jan 1;29(1):25-31.
- (360) Hertel, Pernille Bræmer. TIMP-1 as a predictive marker for chemotherapy in primary breast cancer. University of Copenhagen, Department of Veterinary Disease Biology; PhD Thesis 2011.
- (361) Jørgensen JT, Møller S, Rasmussen BB, Winther H, Schønau A, Knoop A. High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 FISH pharmDx kit. *Am J Clin Pathol.* 2011 Jul; 136(1):145-51.
- (362) Larsen MS. The Role of Bcl-2 and HER receptors as biomarkers in breast cancer. University of Copenhagen, Faculty of Health Science and Herlev Hospital; PhD Thesis Dec 2011.
- (363) McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson N-O, Bennet AM, Fornander T, Gigante B, Jensen M-B, Peto R, Rahimi K, Taylor CW, Ewertz M. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. *Radiother Oncol* 2011; 100: 167-175.
- (364) Nielsen DL, Bjerre KD, Jakobsen EH, Cold S, Stenbygaard L, Sørensen PG, Kamby C, Møller S, Jørgensen CL, Andersson M. Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group. *J Clin Oncol.* 2011 Dec 20; 29(36): 4748-54.
- (365) Nielsen KV, Ejlertsen B, Müller S, Møller S, Rasmussen BB, Balslev E, Lænkholm AV, Christiansen P, Mouridsen HT. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. *Breast Cancer Res Treat* 2011; 127: 345-355.
- (366) O'Connor M, Christensen S, Jensen AB, Møller S, Zachariae R. How traumatic is breast cancer? Post-traumatic stress symptoms (PTSS) and risk factors for severe PTSS at 3 and 15 months after surgery in a nationwide cohort of Danish women treated for primary breast cancer. *Br J Cancer* 2011 Feb 1;104(3): 419-26.



- (367) Pedersen AN, Møller S, Steffensen KD, Haahr V, Jensen M, Kempel MM, Jepsen SL, Madsen EL, Roslind A, Sandberg E, Schöllkopf C, Sørensen PG, Windfeldt KM, Andersson M. Supraclavicular recurrence after early breast cancer: a curable condition? *Breast Cancer Res Treat.* 2011 Feb; 125(3): 815-22.
- (368) Suppli NP, Deltour I, Damkjær LH, Christensen J, Jensen AB, Kroman NT, Johansen C & Dalton SO. Factors associated with the prescription of antidepressive medication to breast cancer patients. *Acta Oncol* 2011; 50: 243–251.
- (369) Taylor CW, Brønnum D, Darby SC, Gagliardi G, Hall P, Jensen M-B, McGale P, Nisbet A, Ewertz M. Cardiac dose estimates from Danish and Swedish breast cancer radiotherapy during 1977–2001. *Radiother Oncol* 2011; 100: 176-183.
- (370) Tvedskov TF, Bartels A, Jensen M-B, Paaschburg B, Kroman N, Balslev E and Brüner N. Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node. *APMIS* 2011 Dec; 119(12):844-52.
- (371) Tvedskov TF, Jensen M-B, Balslev E, Ejlersen B, Kroman N. Stage migration after introduction of sentinel lymph node dissection in breast cancer treatment in Denmark: A nationwide study. *Eur J Cancer* 2011 Apr;47(6):872-878.

## 2012

- (372) Andersen KG, Jensen MB, Kehlet H, Gärtner R, Eckhoff L, Kroman N. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. *Acta Oncol.* 2012 Nov; 51(8):1036-44.
- (373) Bigaard J, Stahlberg C, Jensen MB, Ewertz M, Kroman N. Breast cancer incidence by estrogen receptor status in Denmark from 1996 to 2007. *Breast Cancer Res Treat.* 2012 Nov; 136(2): 559-64.
- (374) Ejlersen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, Lykkesfeldt AE, Müller S, Gelber RD, Price KN, Rasmussen BB, Viale G, Mouridsen H; for the Danish Breast Cancer Cooperative Group, the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. *Ann Oncol.* 2012 Maj; 23(5):1138-1144.
- (375) El-Charnoubi WA, Svendsen JB, Tange UB, Kroman N. Women with inoperable or locally advanced breast cancer - what characterizes them? A retrospective review of 157 cases. *Acta Oncol* 2012 Nov;51(8):1081-5.
- (376) Ewertz M, Gray KP, Regan MM, Ejlersen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HT. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. *J Clin Oncol.* 2012 Nov 10;30(32): 3967-75.
- (377) Hertel PB, Tu D, Ejlersen B, Jensen M-B, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brüner N, Nielsen TO. TIMP-1 in combination with HER2 and TOP2 for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. *Breast Cancer Res Treat* (2012) 132: 225-234.

- (378) Jensen JD, Knoop A, Lænkholm AV, Grauslund M, Jensen M-B, Santoni-Rugiu E, Andersson M, Ewertz M. 2PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. *Ann Oncol.* 2012 Aug; 23(8): 2034-42.
- (379) Kamper-Jørgensen M, Biggar RJ, Tjønneland A, Hjalgrim H, Kroman N, Rostgaard K, et al. Opposite effects of microchimerism on breast and colon cancer. *Eur J Cancer* 2012 Sep;48(14): 2227-35.
- (380) Land LH, Dalton SO, Jensen M-B, Ewertz M. Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008. *Breast Cancer Res Treat.* 2012 Feb;131(3):1013-20.
- (381) Land LH, Dalton SO, Jensen M-B, Ewertz M. Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. *Br J Cancer* (2012) 107, 1901-1907.
- (382) Larsen MS, Bjerre K, Giobbie-Hurder A, Lænkholm AV, Henriksen KL, Ejlersen B, Lykkesfeldt AE, Rasmussen BB. Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy. *Acta Oncol.* 2012 Jul;51(6):781-9
- (383) Larsen MS, Bjerre K, Lykkesfeldt AE, Giobbie-Hurder A, Lænkholm AV, Henriksen KL, Ejlersen B, Rasmussen BB. Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. *Breast.* 2012 Oct;21(5):662-8
- (384) Lænkholm A-V, Knoop A, Ejlersen B, Rudbeck T, Jensen M-B, Müller S, Lykkesfeldt AE, Rasmussen BB, Nielsen KV. ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. *Mol Oncol* 2012 Aug; 6(4): 428-436.
- (385) Meretoja TJ, Leidenius MHK, Heikkilä PS, Boross G, Sejben I, Regitnig P, Luschin-Ebengreuth G, Žgajnar J, Perhavec A, Gazic B, Lázár G, Takács T, Vörös A, Saidan ZA, Nadeem RM, Castellano I, Sapino A, Bianchi S, Vezzosi V, Barranger E, Lousquy R, Arisio R, Foschini MP, Imoto S, Kamma H, Tvedskov TF, Kroman N, Jensen M-B, Audisio RA, Cserni G. International multicenter tool to predict the risk of nonsentinel node metastases in breast cancer. *J Natl Cancer Inst* 2012 Dec 19;104(24): 1888-1896.
- (386) Nielsen KV, Ejlersen B, Møller S, Jensen M-B, Balslev E, Müller S, Knoop A, Mouridsen HT. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. *Mol Oncol.* 2012 Feb; 6(1):88-97.
- (387) Teilum D, Bjerre KD, Tjønneland AM, Kroman N. Breast cancer survival and season of surgery: an ecological open cohort study. *BMJ Open* 2012; 2(1): e000358.
- (388) Tvedskov TF, Jensen M-B, Kroman N, Balslev E. Iatrogenic displacement of tumor cells to the sentinel node after surgical excision in primary breast cancer. *Breast Cancer Res Treat.* 2012 Jan;131(1): 223-9.
- (389) Tvedskov TF, Jensen M-B, Lisse IM, Ejlersen B, Balslev E, Kroman N. High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel node. *Int J Cancer.* 2012 Nov 15;131(10): 2367-75.

**2013**

- (390) Andersen KG, Jensen MB, Tvedskov TF, Kehlet H, Gartner R, Kroman N. Persistent pain, sensory disturbances and functional impairment after immediate or delayed axillary lymph node dissection. *Eur J Surg Oncol* 2013; 39(1):31-35.
- (391) Anderson WF, Rosenberg PS, Petito L, Katki HA, Ejlertsen B, Ewertz D M, Rasmussen BB, Jensen MB, Kroman N. Divergent estrogen receptor positive and negative breast cancer trends and etiologic heterogeneity in Denmark. *Int J Cancer*. 2013 Nov;133(9):2201-6.
- (392) Bjerre C, Knoop A, Bjerre K, Larsen MS, Henriksen KL, Lyng MB, Ditzel HJ, Rasmussen BB, Brünner N, Ejlertsen B, Laenkholm AV. Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer. *Acta Oncol*. 2013 Jan;52(1):82-90.
- (393) Damgaard OE, Jensen MB, Kroman N, Tvedskov TF. Quantifying the number of lymph nodes identified in one-stage versus two-stage axillary dissection in breast cancer. *Breast* 2013 Feb;22(1):44-6.
- (394) Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen M-B, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Eng J Med* 2013 Marts 14; 368: 987-98.
- (395) Eckhoff L, Knoop AS, Jensen MB, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. *Breast Cancer Res Treat* 2013; 142(1):109-18.
- (396) Ejlertsen B, Jensen MB, Elversang J, Rasmussen BB, Andersson M, Andersen J, Nielsen DL, Cold S, Mouridsen HT. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. *Eur J Cancer*. 2013 Sep;49(14):2986-94.
- (397) Grantzau, T., Mellemkjær, L. & Overgaard, J. Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG). *Radiother Oncol*. 2013 Jan;106(1):42-9.
- (398) Hatem A, Azim Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, Leticia De Mattos-Arruda, Pistilli B, Pinto A, Jensen M-B, Cordoba O, Evandro de Azambuja, Goldhirsch A, Piccart MJ, and Peccatori FA. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. *J Clin Oncol*. 2013 Jan 1;31(1):73-9.
- (399) Holm M, Olsen A, Christensen J, Kroman NT, Bidstrup PE, Johansen C, et al. Pre-diagnostic alcohol consumption and breast cancer recurrence and mortality: Results from a prospective cohort with a wide range of variation in alcohol intake. *Int J Cancer* 2013 Feb 1;132(3):686-94.
- (400) Jørgensen CLT, Ejlertsen B, Bjerre KD, Balslev E, Nielsen DL, Nielsen KV. Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine. *BMC Cancer* November 2013, 13:541.
- (401) Lyng MB, Lænkholm AV, Tan Q, Vach W, Gravgaard KH, Knoop A, Ditzel HJ. Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study. *PLoS One*. 2013;8(1):e54078.

- (402) Lyngholm CD, Christiansen PM, Damsgaard TE, Overgaard J. Long-term follow-up of late morbidity, cosmetic outcome and body image after breast conserving therapy. A study from the Danish Breast Cancer Cooperative Group (DBCG). *Acta Oncol.* 2013 Feb;52(2):259-69.
- (403) Mejdahl MK, Andersen KG, Gärtner R, Kroman N, Kehlet H. Persistent pain and sensory disturbances after treatment for breast cancer: six year nationwide follow-up study. *BMJ.* 2013 Apr 11;346:f1865.
- (404) Meretoja TJ, Audisio RA, Heikkilä PS, Bori R, Seiben I, Regitnig P, Luschin-Ebengreuth G, Zgajnar J, Perhavec A, Gazic B, Lázár G, Takács T, Kővári B, Saidan ZA, Nadeem RM, Castellano I, Sapino A, Bianchi S, Vezzosi V, Barranger E, Lousquy R, Arisio R, Foschini MP, Imoto S, Kamma H, Tvedskov TF, Jensen M-B, Cserni G, Leidenius MH. International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases. *Breast Cancer Res Treat.* 2013 Apr;138(3):817-27.
- (405) Nielsen MH, Berg M, Pedersen AN, Andersen K, Glavicic V, Jakobsen EH, Jensen I, Josipovic M, Lorenzen EL, Nielsen HM, Stenbygaard L, Thomsen MS, Vallentin S, Zimmermann S, Offersen BV; Danish Breast Cancer Cooperative Group Radiotherapy Committee. Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: national guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group. *Acta Oncol.* 2013 May;52(4):703-10.
- (406) Pedersen CG, Christensen S, Jensen AB, Zachariae R. Use of complementary and alternative medicine (CAM) and changes in depressive symptoms from 3 to 15 months after surgery for primary breast cancer: results from a nationwide cohort study. *Breast Cancer Res Treat.* 2013 Sep;141(2):277-85.
- (407) Sørensen GV, Ganz PA, Cole SW, Pedersen LA, Sørensen HT, Cronin-Fenton DP, Garne JP, Christiansen PM, Lash TL, Ahern TP. Use of  $\beta$ -blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. *J Clin Oncol.* 2013 Jun 20;31(18):2265-72.
- (408) Thorsen LB, Thomsen MS, Overgaard M, Overgaard J, Offersen BV; Danish Breast Cancer Cooperative Group Radiotherapy Committee. Quality assurance of conventional non-CT-based internal mammary lymph node irradiation in a prospective Danish Breast Cancer Cooperative Group trial: the DBCG-IMN study. *Acta Oncol.* 2013 Oct;52(7):1526-34.

## 2014

- (409) Ahern TP, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP. Statins and breast cancer prognosis: evidence and opportunities. *Lancet Oncol* 2014 Sept; 15: e461–68
- (410) Andersen C, Rørth M, Ejlersen B, Adamsen L. Exercise despite pain: breast cancer patient experiences of muscle and joint pain during adjuvant chemotherapy and concurrent participation in an exercise intervention. *Eur J Cancer Care (Engl)* 2014;23(5):653-67.
- (411) Christiansen P, Vejborg I, Kroman N, Holten I, Garne JP, Vedsted P, Møller S, Lyng E. Position paper: Breast cancer screening, diagnosis, and treatment in Denmark. *Acta Oncol.* 2014 Apr; 53(4): 433–444.
- (412) Ejlersen B, Jensen MB, Mouridsen HT. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. *Acta Oncol.* 2014 Feb; 53(2):174-85.

- (413) Gärtner R, Mejdahl MK, Andersen KG, Ewertz M, Kroman N. Development in self-reported arm-lymphedema in Danish women treated for early-stage breast cancer in 2005 and 2006--a nationwide follow-up study. *Breast*. 2014; 23(4):445-52.
- (414) Holm M, Olsen A, Kroman N, Tjønneland A. Lifestyle influences on the association between pre-diagnostic hormone replacement therapy and breast cancer prognosis-Results from The Danish 'Diet, Cancer and Health' prospective cohort. *Maturitas*. 2014 Dec; 79(4):442-8
- (415) Huober J, Cole BF, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B, Bonnefoi H, Forbes JF, Neven P, Lang I, Smith I, Wardley A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Gelber RD, Thurlimann B for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. *Breast Cancer Res Treat*. 2014; 143:159-69.
- (416) Jørgensen CL, Bjerre C, Ejlertsen B, Bjerre KD, Balslev E, Bartels A, Brüner N, Nielsen, DL. TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group. *BMC Cancer*. 2014 May 22;14:360.
- (417) Jørgensen CL, Nielsen TO, Bjerre KD, Liu S, Wallden B, Balslev E, Nielsen DL, Ejlertsen B. PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients. *Acta Oncol*. 2014 Jun; 53(6):776-87.
- (418) Klit A, Henriksen TF, Siersen HE, Elberg JJ, Christiansen P, Kroman N. Onkoplastisk brystkirurgi i Danmark. *Ugeskr Læger*. 2014;176:V06130376
- (419) Knoop AS, Lænkholm AV, Jensen MB, Nielsen KV, Andersen J, Nielsen D, Ejlertsen B. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. *Eur J Cancer*. 2014 May; 50(8):1412-21.
- (420) Lietzen LW, Ahern T, Christiansen P, Jensen AB, Sørensen HT, Lash TL, Cronin-Fenton DP. Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study. *Ann Oncol*. 2014 Dec; 25(12):2419-25.
- (421) McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet*. 2014 Jun 21;383(9935):2127-35.
- (422) Mellekjær L, Steding-Jessen M, Frederiksen K, Andersson M, Ejlertsen B, Jensen MB, Olsen JH. Risk of contralateral breast cancer after tamoxifen use among Danish women. *Ann Epidemiol*. 2014 Nov; 24(11):843-8.
- (423) Rasmussen CB, Kjær SK, Ejlertsen B, Andersson M, Jensen MB, Christensen J, Langballe R, Mellekjær L. Incidence of metachronous contralateral breast cancer in Denmark 1978-2009. *Int J Epidemiol*. 2014 Dec; 43(6):1855-64
- (424) Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B, Finkelstein DM, Rappold E, Curran J, Cardon LR, Goss PE. Prospective Validation of HLA-DRB1\*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury. *J Clin Oncol*. 2014 Aug 1; 32(22):2296-303.
- (425) Suppli NP, Johansen Ch, Christensen J, Kessing LV, Kroman N, Dalton SO. Increased Risk for Depression After Breast Cancer: A Nationwide Population-Based Cohort Study of Associated Factors in Denmark. 1998-2011. *J Clin Oncol*. 2014 Dec 1;32(34):3831-9

- (426) Tvedskov TF, Jensen MB, Balslev E, Kroman N. Robust and validated models to predict high risk of non-sentinel node metastases in breast cancer patients with micrometastases or isolated tumor cells in the sentinel node. *Acta Oncol.* 2014 Feb;53(2):209-15.

## 2015

- (427) Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O'Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. *J Clin Oncol.* 2015 May 20;33(15):1680-7.
- (428) Bodilsen A, Bjerre K, Offersen BV, Vahl P, Ejlertsen B, Overgaard J, Christiansen P. The Influence of Repeat Surgery and Residual Disease on Recurrence After Breast-Conserving Surgery: A Danish Breast Cancer Cooperative Group Study. *Ann Surg Oncol.* 2015 Dec;22 Suppl 3:476-85.
- (429) Bodilsen A, Christensen S, Christiansen P, Damsgaard TE, Zachariae R, Jensen AB. Socio-demographic, clinical, and health-related factors associated with breast reconstruction - A nationwide cohort study. *Breast.* 2015 Oct;24(5):560-7.
- (430) Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE; TEACH Investigators. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. *Eur J Cancer.* 2015 Apr;51(6):685-96.
- (431) Christiansen P, Vejborg I, Kroman N, Holten I, Garne JP, Vedsted P, Møller S, Lyng E. Comments to the paper: Influence of mammography screening on use of mastectomies in Denmark. *Acta Oncol.* 2015 Jan;54(1):135-6.
- (432) Cronin-Fenton DP, Heide-Jørgensen U, Ahern TP, Lash TL, Christiansen PM, Ejlertsen B, Sjøgren P, Kehlet H, Sørensen HT. Opioids and breast cancer recurrence: A Danish population-based cohort study. *Cancer.* 2015 Oct 1;121(19):3507-14.
- (433) Goldrat O, Kroman N, Peccatori FA, Cordoba O, Pistilli B, Lidsgaard O, Demeestere I, Azim HA Jr. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. *Eur J Cancer.* 2015 Aug;51(12):1490-6.
- (434) Holm-Rasmussen EV, Jensen MB, Balslev E, Kroman N, Tvedskov TF. Reduced risk of axillary lymphatic spread in triple-negative breast cancer. *Breast Cancer Res Treat.* 2015 Jan;149(1):229-36.
- (435) Lietzen LW, Cronin-Fenton D, Christiansen P, Sørensen HT, Lash TL. Autoimmune diseases and breast cancer recurrence: a Danish nationwide cohort study. *Breast Cancer Res Treat.* 2015 Jan;149(2):497-504.
- (436) Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Debled M, Price KN, Regan MM, Coates AS, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. *J Clin Oncol.* 2015 Sep 1;33(25):2772-9.
- (437) Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni

M; International Breast Cancer Study Group and the BIG 1-98 Collaborative Group. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. *Ann Oncol.* 2015 Dec;26(12):2442-9.

- (438) Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. *Breast Cancer Res.* 2015 Apr 16;17:56.
- (439) Tvedskov TF, Jensen MB, Ejlertsen B, Christiansen P, Balslev E, Kroman N. Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study. *Breast Cancer Res Treat.* 2015 Oct;153(3):599-606.

## 2016

- (440) Anderson WF, Pfeiffer RM, Wohlfahrt J, Ejlertsen B, Jensen MB, Kroman N. Associations of parity-related reproductive histories with ER± and HER2± receptor-specific breast cancer aetiology. *Int J Epidemiol.* 2016 Nov 6. [Epub ahead of print]
- (441) Bloomquist K, Hayes S, Adamsen L, Moller T, Christensen KB, Ejlertsen B, et al. A randomized cross-over trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema: study protocol. *BMC Cancer.* 2016 Jul 22;16:517
- (442) Bodilsen A, Bjerre K, Offersen BV, Vahl P, Amby N, Dixon JM, Ejlertsen B, Overgaard J, Christiansen P. Importance of margin width in breast-conserving treatment of early breast cancer. *J Surg Oncol.* 2016 May;113(6):609-15.
- (443) Bodilsen A, Offersen BV, Christiansen P, Overgaard J. Pattern of relapse after breast conserving therapy, a study of 1519 early breast cancer patients treated in the Central Region of Denmark 2000-2009. *Acta Oncol.* 2016 Aug;55(8):964-9.
- (444) Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2016 Mar;17(3):367-77.
- (445) Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, et al. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. *J Clin Oncol.* 2016;34(21):2452-9.
- (446) Christiansen P, Ejlertsen B, Jensen MB, Mouridsen H. Danish Breast Cancer Cooperative Group. *Clinical Epidemiology* 2016 Oct 25;8:445-449
- (447) Cronin-Fenton DP, Heide-Jørgensen U, Ahern TP, Lash TL, Christiansen P, Ejlertsen B, Sørensen HT. Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence. *Epidemiology.* 2016 Jul;27(4):586-93.
- (448) Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nat Genet.* 2016;48(4):374-86.
- (449) Ejlertsen B. Adjuvant chemotherapy in early breast cancer. *Dan Med J.* 2016 May;63(5). pii: B5222.

- (450) Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel. *Ann Oncol.* 2016 Mar;27(3):379-90.
- (451) Jensen MB, Ejlertsen B, Mouridsen HT, Christiansen P; for the Danish Breast Cancer Cooperative Group. Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment. *Acta Oncol.* 2016 Jun;55 Suppl 2:24-35.
- (452) Jonson L, Ahlborn LB, Steffensen AY, Djursby M, Ejlertsen B, Timshel S, et al. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer. *Breast Cancer Res Treat.* 2016;155(2):215-22.
- (453) Juhl AA, Christiansen P, Damsgaard TE. Persistent Pain after Breast Cancer Treatment: A Questionnaire-Based Study on the Prevalence, Associated Treatment Variables, and Pain Type. *J Breast Cancer.* 2016 Dec;19(4):447-454.
- (454) Kumler I, Knoop AS, Jessing CA, Ejlertsen B, Nielsen DL. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. *ESMO Open.* 2016 Aug 16;1(4):e000062.
- (455) Laurberg T, Lyngholm CD, Christiansen P, Alsner J, Overgaard J. Long-term age-dependent failure pattern after breast-conserving therapy or mastectomy among Danish lymph-node-negative breast cancer patients. *Radiother Oncol.* 2016 Jul;120(1):98-106.
- (456) Lawrenson K, Kar S, McCue K, Kuchenbaecker K, Michailidou K, Tyrer J, et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nat Commun.* 2016 Sep 7;7:12675.
- (457) Lyngholm CD, Laurberg T, Alsner J, Damsgaard TE, Overgaard J, Christiansen PM. Failure pattern and survival after breast conserving therapy. Long-term results of the Danish Breast Cancer Group (DBCG) 89 TM cohort. *Acta Oncol.* 2016 Aug;55(8):983-92.
- (458) Nielsen TO, Jensen MB, Burugu S, Gao D, Jorgensen CLT, Balslev E, Ejlertsen B. High risk premenopausal Luminal A breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: results from the DBCG77B clinical trial. *Clinical Cancer Research.* 2016 Sep; 22(17).
- (459) Rottmann N, Hansen DG, Hagedoorn M, Larsen PV, Nicolaisen A, Bidstrup PE, Würtzen H, Flyger H, Kroman N, Johansen C. Depressive symptom trajectories in women affected by breast cancer and their male partners: a nationwide prospective cohort study. *J Cancer Surviv.* 2016 Oct;10(5):915-26
- (460) Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Res.* 2016 Feb 9;18(1):15.
- (461) Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, et al. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. *Eur J Cancer.* 2016;56:85-92.
- (462) Tvedskov TF, Jensen MB, Balslev E, Garne JP, Vejborg I, Christiansen P, Ejlertsen B, Kroman N. Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers. *Acta Oncol.* 2016;55(4):455-9.



- (463) Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, et al. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS One*. 2016;11(7):e0158801.
- (464) Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, et al. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Res*. 2016;18(1):64.

## 2017

- (465) Ahern TP, Hertz DL, Damkier P, Ejlersen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. *Am J Epidemiol*. 2017 Jan 15;185(2):75-85.
- (466) Alkner S, Jensen MB, Rasmussen BB, Bendahl PO, Fernö M, Rydén L, Mouridsen H; Danish Breast Cancer Cooperative Group. Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98. *Breast Cancer Res Treat*. 2017 Nov;166(2):481-490.
- (467) Anderson WF, Pfeiffer RM, Wohlfahrt J, Ejlersen B, Jensen MB, Kroman N. Associations of parity-related reproductive histories with ER± and HER2± receptor-specific breast cancer aetiology. *Int J Epidemiol*. 2017 Feb 1;46(1):86-95.
- (468) Borgquist S, Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Láng I, Debled M, Ejlersen B, von Moos R, Smith I, Coates AS, Goldhirsch A, Rabaglio M, Price KN, Gelber RD, Regan MM, Thürlimann B. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. *J Clin Oncol*. 2017 Apr 10;35(11):1179-1188.
- (469) Cronin-Fenton DP, Kjærsgaard A, Ahern TP, Mele M, Ewertz M, Hamilton-Dutoit S, Christiansen PM, Ejlersen B, Sørensen HT, Lash TL, Silliman RA. Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study. *Acta Oncol*. 2017 Sep; 56(9):1155-1160.
- (470) Curigliano G, Burstein HJ, P Winer E, Gnani M, Dubsy P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol*. 2017 Aug 1;28(8):1700-1712.
- (471) Curigliano G, Burstein HJ, Winer EP, Gnani M, Dubsy P, Loibl S, et al. Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. *Ann Oncol*. 2017 Sep 25.
- (472) Ejlersen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Højris I, Ewertz M, Balslev E, Danø H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. *J Clin Oncol* 2017; 35(23):2639:2646.
- (473) Hamdi Y, Soucy P, Kuchenbaecker KB, Pastinen T, Droit A, Lemaçon A, et al. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Res Treat*. 2017 Jan;161(1):117-134.

- (474) Holm-Rasmussen EV, Jensen MB, Balslev E, Kroman N, Tvedskov TF. The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study. *Eur J Cancer*. 2017 Dec;87:1-9.
- (475) Klit A, Tvedskov TF, Kroman N, Elberg JJ, Ejlersen B, Henriksen TF. Oncoplastic breast surgery does not delay the onset of adjuvant chemotherapy: a population-based study. *Acta Oncol*. 2017 May;56(5):719-723.
- (476) Kolstad HA, Garde AH, Hansen ÅM, Frydenberg M, Christiansen P, Vistisen HT, Bonde JP. Response to Dr Stevens' letter ref. Vistisen et al: "Short-term effects of night shift work on breast cancer risk: a cohort study of payroll data". *Scand J Work Environ Health*. 2017 Jan 1;43(1):96.
- (477) Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G, Jensen MB, Gelber S, Del Grande M, Ignatiadis M, de Azambuja E, Paesmans M, Peccatori FA, Azim HA Jr. Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. *J Natl Cancer Inst*. 2017. [Epub ahead of print]
- (478) Langhans L, Jensen MB, Talman MM, Vejborg I, Kroman N, Tvedskov TF. Reoperation Rates in Ductal Carcinoma In Situ vs Invasive Breast Cancer After Wire-Guided Breast-Conserving Surgery. *JAMA Surg*. 2017 Apr 1;152(4):378-384.
- (479) Laurberg T, Alsner J, Tramm T, Jensen V, Lyngholm CD, Christiansen PM, Overgaard J. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients. *Acta Oncol*. 2017 Jan; 56(1):59-67.
- (480) Lyng E, Beau AB, Christiansen P, von Euler-Chelpin M, Kroman N, Njor S, Vejborg I. Overdiagnosis in breast cancer screening: The impact of study design and calculations. *Eur J Cancer*. 2017 Jul; 80:26-29.
- (481) Martin M, Holmes FA, Ejlersen B, Delaloge S, Moy B, Iwata H, et al; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2017 Dec;18(12):1688-1700.
- (482) Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nat Genet*. 2017 Dec;49(12):1767-1778.
- (483) Nielsen TO, Jensen MB, Burugu S, Gao D, Jørgensen CL, Balslev E, Ejlersen B. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. *Clin Cancer Res*. 2017 Feb 15;23(4):946-953.
- (484) Pedersen RN, Bhaskaran K, Heide-Jørgensen U, Nørgaard M, Christiansen PM, Kroman N, Sørensen HT, Cronin-Fenton DP. Breast cancer recurrence after reoperation for surgical bleeding. *Br J Surg*. 2017 Nov; 104(12): 1665–1674.
- (485) Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet*. 2017 May;49(5):680-691.
- (486) Rehammar JC, Jensen MB, McGale P, Lorenzen EL, Taylor C, Darby SC, Videbæk L, Wang Z, Ewertz M. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines

- among 19,464 breast cancer patients in Denmark, 1977-2005. *Radiother Oncol.* 2017 May; 123(2): 299–305.
- (487) Rehammar JC, Johansen JB, Jensen MB, Videbæk L, Jørgensen OD, Lorenzen E, Ewertz M. Risk of pacemaker or implantable cardioverter defibrillator after radiotherapy for early-stage breast cancer in Denmark, 1982-2005. *Radiother Oncol.* 2017 Jan;122(1):60-65
- (488) Rottmann N, Gilsa HD, dePont CR, Hagedoorn M, Frisch M, Nicolaisen A, Kroman N, Flyger H, Johansen C. Satisfaction with sex life in sexually active heterosexual couples dealing with breast cancer: a nationwide longitudinal study. *Acta Oncol* 2017 Jan 12;1-8.
- (489) Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, et al. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. *J Clin Oncol.* 2017 Apr 1;35(10):1041-1048.
- (490) Suppli NP, Johansen C, Kessing LV, Toender A, Kroman N, Ewertz M, Dalton SO. Survival After Early-Stage Breast Cancer of Women Previously Treated for Depression: A Nationwide Danish Cohort Study. *J Clin Oncol* 2017 Jan 20;35(3):334-42.
- (491) Thomsen AML, Pedersen AB, Kristensen NR, Møller BK, Erikstrup C, Christiansen PM, Nørgaard M, Cronin-Fenton D. Use of prescription drugs and risk of postoperative red blood cell transfusion in breast cancer patients: a Danish population-based cohort study. *Breast Cancer Res.* 2017 Dec 22; 19(1):135.
- (492) Vistisen HT, Garde AH, Frydenberg M, Christiansen P, Hansen ÅM, Andersen J, Bonde JP, Kolstad HA. Short-term effects of night shift work on breast cancer risk: a cohort study of payroll data. *Scand J Work Environ Health.* 2017 Jan 1;43(1):59-67.
- (493) Weischenfeldt KLH, Kirkegaard T, Rasmussen BB, Giobbie-Hurder A, Jensen MB, Ejlertsen B, Lykkesfeldt AE. A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis. *Acta Oncol.* 2017 Sep;56(9):1161-1167.
- 2018**
- (494) Banke A, Fosbøl EL, Møller JE, Gislason GH, Andersen M, Bernsdorf M, Jensen MB, Schou M, Ejlertsen B. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. *Eur J Heart Fail.* 2018 Mar 1. [Epub ahead of print]
- (495) Berg M, Lorenzen EL, Jensen I, Thomsen MS, Lutz CM, Refsgaard L, et al. The potential benefits from respiratory gating for breast cancer patients regarding target coverage and dose to organs at risk when applying strict dose limits to the heart: results from the DBCG HYPO trial. *Acta Oncol.* 2018;57(1):113-9.
- (496) Bloomquist K, Oturai P, Steele ML, Adamsen L, Møller T, Christensen KB, Ejlertsen B, Hayes SC. Heavy-Load Lifting: Acute Response in Breast Cancer Survivors at Risk for Lymphedema. *Med Sci Sports Exerc.* 2018 Feb;50(2):187-195.
- (497) Brink C, Lorenzen EL, Krogh SL, Westberg J, Berg M, Jensen I, et al. DBCG hypo trial validation of radiotherapy parameters from a national data bank versus manual reporting. *Acta Oncol.* 2018;57(1):107-12.
- (498) Bundesen E. Breast cancer patient advocacy in Denmark. *Acta Oncol.* 2018;57(1):152-3.

- (499) Christiansen P, Carstensen SL, Ejlertsen B, Kroman N, Offersen B, Bodilsen A, Jensen MB. Breast conserving surgery versus mastectomy: overall and relative survival-a population based study by the Danish Breast Cancer Cooperative Group (DBCG). *Acta Oncol.* 2018 Jan; 57(1):19-25.
- (500) Cronin-Fenton D, Lash TL, Ahern TP, Damkier P, Christiansen P, Ejlertsen B, Sørensen HT. Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database. *Acta Oncol.* 2018 Jan;57(1):120-128.
- (501) Dalton SO, Suppli NP, Ewertz M, Kroman N, Grassi L, Johansen C. Impact of schizophrenia and related disorders on mortality from breast cancer: A population-based cohort study in Denmark, 1995-2011. *Breast.* 2018;170-176.
- (502) Ejlertsen B, Offersen BV, Overgaard J, Christiansen P, Jensen MB, Kroman N, Knoop AS, Mouridsen H. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. *Acta Oncol* 2018 Jan;57(1):3-12.
- (503) Ewertz M, Land LH, Dalton SO, Cronin-Fenton D, Jensen MB. Influence of specific comorbidities on survival after early-stage breast cancer. *Acta Oncol* 2018;57(1):129-34.
- (504) Hamran K, Langhans L, Vejborg I, Tvedskov TF, Kroman N. The accuracy of preoperative staging of the axilla in primary breast cancer: a national register based study on behalf of Danish Breast Cancer Group (DBCG). *Acta Oncol.* 2018;57(1):162-6.
- (505) Holm-Rasmussen EV, Jensen MB, Balslev E, Kroman N, Tvedskov TF. Risk factors of sentinel and non-sentinel lymph node metastases in patients with ductal carcinoma in situ of the breast: A nationwide study. *The Breast*, 2018 Dec; 42:128-132
- (506) Jensen MB, Krarup JF, Palshof T, Mouridsen HT, Ejlertsen B. Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial. *Acta Oncol.* 2018 Jan;57(1):26-30.
- (507) Jensen MB, Lænkholm AV, Nielsen TO, Eriksen JO, Wehn P, Hood T, Ram N, Buckingham W, Ferree S, Ejlertsen B. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. *Breast Cancer Res.* 2018 Jul 27;20(1):79.
- (508) Jensen MB, Lænkholm AV, Offersen BV, Christiansen P, Kroman N, Mouridsen HT, Ejlertsen B. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016. *Acta Oncol* 2018 Jan;57(1):13-18.
- (509) Jensen MB, Nielsen TO, Knoop AS, Lænkholm AV, Balslev E, Ejlertsen B. Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials. *Acta Oncol.* 2018 Jan;57(1):135-140.
- (510) Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, Özgüroglu M, Landherr L, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau AL, Burris H. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. *JAMA Oncol.* 2018 Jun 3 [Epub ahead of print]
- (511) Jessing C, Langhans L, Jensen MB, Talman ML, Tvedskov TF, Kroman N. Axillary lymph node dissection in breast cancer patients after sentinel node biopsy. *Acta Oncol.* 2018;57(1):166-9.
- (512) Kinalis S, Nielsen FC, Talman ML, Ejlertsen B, Rossing M. Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort. *Acta Oncol.* 2018 Jan;57(1):51-57.

- (513) Kristensen B, Ejlertsen B, Jensen MB, Mouridsen HT; Danish Breast Cancer Cooperative Group. The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study. *Acta Oncol.* 2018 Jan;57(1):141-145.
- (514) Laenkholm AV, Grabau D, Moller Talman ML, Balslev E, Bak Jylling AM, Tabor TP, Johansen M, Brüggman A, Ielkaitis G, Caterino TD, Mygind H, Poulsen T, Mertz H, Søndergaard G, Rasmussen BB. An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG). *Acta Oncol.* 2018;57(1):83-9.
- (515) Laenkholm AV, Jensen MB, Eriksen JO, Buckingham W, Ferree S, Nielsen TO, Ejlertsen B. The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptorpositive postmenopausal women with special histological subtypes. *Acta Oncol* 2018 Jan;57(1):44-50.
- (516) Laenkholm AV, Jensen MB, Eriksen JO, Rasmussen BB, Knoop AS, Buckingham W, Ferree S, Schaper C, Nielsen TO, Haffner T, Kibøl T, Møller Talman ML, Bak Jylling AM, Tabor TP, Ejlertsen B. PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. *J Clin Oncol.* 2018 Mar 10;36(8):735-740.
- (517) Langballe R, Frederiksen K, Jensen MB, Andersson M, Cronin-Fenton D, Ejlertsen B, Mellemkjær L. Mortality after contralateral breast cancer in Denmark. *Breast Cancer Res Treat.* 2018; 1-11.
- (518) Laurberg T, Tramm T, Nielsen T, Alsner J, Nord S, Myhre S, Sørlie T, Leung S, Fan C, Perou C, Gelmon K, Overgaard J, Voduc D, Prat A, Cheang MCU. Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. *Acta Oncol.* 2018;57(1):38-43.
- (519) Lee Mortensen G, Madsen IB, Krogsgaard R, Ejlertsen B. Quality of life and care needs in women with estrogen positive metastatic breast cancer: a qualitative study. *Acta Oncol.* 2018 Jan;57(1):146-51.
- (520) Lykkesfeldt AE, Iversen BR, Jensen MB, Ejlertsen B, Giobbie-Hurder A, Reiter BE, Kirkegaard T, Rasmussen BB. Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. *Acta Oncol.* 2018 Jan;57(1):67-73.
- (521) Meyer L, Bille C, Foged T, Jylling AMB. Occult breast cancer in breast reduction specimens. *Acta Oncol.* 2018;57(1):170-3.
- (522) Moghadasi S, Meeks HD, Vreeswijk MP, Janssen LA, Borg Å, Ehrencrona H, et al. The BRCA1 c.5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. *J Med Genet.* 2018 Jan;55(1):15-20.
- (523) Mouridsen H, Christiansen P, Jensen MB, Laenkholm AV, Flyger H, Offersen B, Vejborg I, Ejlertsen B. Provision of data from the clinical database and of biological material from the tumor bank of the Danish Breast Cancer Cooperative Group 2008–2017. *Acta Oncol* 2018 Jan;57(1):154-156.

- (524) Offersen BV, Ejlersen B, Balslev E, Flyger H, Gerdes AM, Hansen MK, Hølmich LR, Jensen MB, Kristensen B, Lænkholm AV, Mouridsen HT, Nielsen MH, Overgaard J, Tuxen M, Vejborg I, Christiansen P. Is DBCG abreast of new developments? *Acta Oncol.* 2018 Jan;57(1):1-2.
- (525) Pedersen IS, Schmidt AY, Bertelsen B, Ernst A, Andersen CLT, Kruse T, et al. A Danish national effort of BRCA1/2 variant classification. *Acta Oncol.* 2018;57(1):159-62.
- (526) Rossing M, Østrup O, Majewski WW, Kinalis S, Jensen MB, Knoop A, Kroman N, Talman ML, Hansen TVO, Ejlersen B, Nielsen FC. Molecular subtyping of breast cancer improves identification of both high and low risk patients. *Acta Oncol.* 2018 Jan;57(1):58-66.
- (527) Rosvig LH, Langkjer ST, Knoop A, Jensen AB. Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer. *Acta Oncol.* 2018;57(1):156-9.
- (528) Skriver SK, Laenkholm AV, Rasmussen BB, Handler J, Grundtmann B, Tvedskov TF, Christiansen P, Knoop AS, Jensen MB, Ejlersen B. Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). *Acta Oncol.* 2018;57(1):31-7.
- (529) Soenderstrup IMH, Laenkholm AV, Jensen MB, Eriksen JO, Gerdes AM, Hansen TVO, Kruse TA, Larsen MJ, Pedersen IS, Rossing M, Thomassen M, Ejlersen B. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. *Acta Oncol.* 2018 Jan;57(1):95-101.
- (530) Stoltze U, Skytte AB, Roed H, Hasle H, Ejlersen B, Overeem Hansen TV, Schmiegelow K, Gerdes AM, Wadt K. Clinical characteristics and registry-validated extended pedigrees of germline TP53 mutation carriers in Denmark. *PLoS One.* 2018 Jan 11;13(1):e0190050.
- (531) Stovgaard ES, Nielsen D, Hogdall E, Balslev E. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review. *Acta Oncol.* 2018;57(1):74-82.
- (532) Sørensen GV, Cronin-Fenton DP, Sørensen HT, Damkier P, Ejlersen B, Christiansen PM, Lash TL, Ahern TP. Re: Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer. *Epidemiology.* 2018 Sep;29(5):e39-e40.
- (533) Taylor C, McGale P, Brønnum D, Correa C, Cutter D, Duane FK, Gigante B, Jensen MB, Lorenzen E, Rahimi K, Wang Z, Darby SC, Hall P, Ewertz M. Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data. *J Clin Oncol.* 2018 Aug 1;36(22):2288-2296.
- (534) Tramm T, Di Caterino T, Jylling AB, Lelkaitis G, Laenkholm AV, Rago P, Tabor TP, Talman MLM, Vouza E. Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists. *Acta Oncol.* 2018;57(1):90-4.
- (535) Tramm T, Kyndi M, Sorensen FB, Overgaard J, Alsner J. Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer. *Acta Oncol.* 2018;57(1):102-6.